In HPA’s more than 30-year history, our team has worked with a wide variety of novel cardiac implants/devices and diagnostic tools. Whether your needs involve assistance with regulatory strategy/submission or clinical trial strategy, design and execution, HPA has the experience and expertise to get your technology from prototype to commercialization. With a proven track record of advancing technology in a streamlined, ultra-efficient fashion that leads to quicker, more economical approvals, HPA can serve as a valuable asset to your cardiovascular company.
Clinical trials and studies must be designed to balance the need for rigor with the need for efficiency and speed. Patient-reported outcomes need to be accurately and consistently gathered, checked and assessed throughout the study rather than after the fact. The process of collecting health economics data needs to be built into your initial study, rather than running a costly additional study after regulatory approval and incurring delays in reimbursement.
HPA has extensive experience working with companies to deliver a wide range of cardiovascular medical device and diagnostic technologies, including but not limited to:
HPA offers senior-led regulatory, clinical, and quality support for medical devices, combination products and biotech.
You can find plenty of partners to run site visits, collect data, or assemble slides.
HPA is different: we are a senior‑led, FDA‑focused team built to help you:
And we do it all with a stable team and predictable budget.
If you’re carrying the pressure of an FDA setback, a critical submission, or a high‑risk trial, you don’t have to navigate it alone.
